CHALLENGES
In oncology, various targeted anti-cancer agents have been developed.
However, they are not effectively helping cancer patients due to inefficient diagnostic methods.
SOLUTION
We advanced the ADPS technology and developed Digital ADPS, which enables high-sensitivity massive multiplex diagnosis with a single test.
This new technology diagnoses actionable markers through massive multiplexing, allowing the test results to be directly applied to treatment. For example, non-small cell lung cancer is diagnosed through the massive multiplex detection of cancer mutations such as EGFR, KRAS, BRAF, EML4-ALK, and ROS1.
Digital ADPS was inspired by the Nested PCR method and completes massive multiplexing by pre-amplifying DNA isolated from tissue or plasma, followed by the detection of each actionable marker. When RNA markers are included, we developed a technology that performs reverse transcription before pre-amplification, followed by sequential PCR to enhance diagnostic efficiency, allowing the analysis of various nucleic acid markers.
Digital ADPS technology has been applied to the ADPS Cancer Panel since its development and will soon be launched as an RUO product.
Work Flow
